Non-injection weight loss: understanding your options and how to decide

The misconception worth clearing up first

A lot of people search for non-injection options because they assume injections are the only way GLP-1 medicines work at meaningful doses. That was true until recently. The approval of Wegovy tablets in June 2026 changes the picture, oral semaglutide, taken as a daily tablet rather than a weekly pen, is now a licensed route for weight management in the UK, according to the NHS guidance on semaglutide.

Orlistat capsules have existed for years as another non-injection option, they work by blocking absorption of roughly a third of dietary fat rather than acting on appetite hormones. They are available on prescription and, at lower doses, over the counter. Results vary considerably and they come with well-known gastrointestinal side effects if fat intake stays high. They suit a specific kind of motivated patient who is also ready to change their diet substantially.

The point is: 'no injections' is no longer a conversation-stopper. It is the start of a more specific conversation about which non-injection route fits your health profile, your daily routine and what your prescriber thinks is appropriate. If you want a structured comparison, our page covering the best non-injection weight loss medication options available in the UK is a good place to start.

What the tablet option actually involves day to day

The Wegovy tablet schedule starts at 1.5mg daily and escalates (through 4mg and 9mg) to a 25mg maintenance dose, with at least a month at each level before moving up. That titration pace exists to reduce gastrointestinal side effects, which are common at the start and in most people ease as the body adjusts. In the OASIS 4 trial, around 74% of participants on oral semaglutide reported GI effects, mostly mild to moderate.

The morning routine matters more than it might sound. Oral semaglutide is poorly absorbed if taken with food or washed down with anything other than a small amount of plain water, up to about 120ml. The 30-minute wait before eating or drinking anything else is part of what makes it work. No refrigeration is needed, which makes the tablet genuinely easier for travel than any of the injectable formats.

If you are already established on the 2.4mg weekly semaglutide injection, a move to the 25mg tablet may be possible clinically, but that is a conversation for your prescriber, not a switch to make unilaterally. You can read more about non-injection weight-loss medicines available in the UK and how they compare in our detailed overview.

How injectable treatments compare (and why some people change their mind

The injection formats) Wegovy (semaglutide) and Mounjaro (tirzepatide), currently have a larger body of long-term evidence behind them. Mounjaro is the only dual-agonist available in the UK, activating both GIP and GLP-1 receptors; in the SURMOUNT-1 trial, average weight reduction at the highest dose was around 20–21% over 72 weeks, as reported in the New England Journal of Medicine. The Wegovy injection at its standard 2.4mg dose produced around 15% average loss in STEP 1.

Many people who were initially hesitant about self-injection find it far less daunting in practice than they imagined, and our guide to weight loss injections walks through exactly what the process looks like, including how pens like the KwikPen used for Mounjaro are pre-filled and straightforward to use. That said, needle phobia is real and valid, and for patients where it is a genuine barrier, an oral route removes it entirely.

The decision usually comes down to three things: how much weight loss evidence matters to you and at what timeline, how your daily routine accommodates each format, and what your prescriber thinks given your full health picture. If you want to explore the injectable options alongside this, our guide to weight-loss injections in the UK covers both in detail, and our page on injections for people without diabetes explains the licensing specifically.

Getting a prescription and what to expect from clinical review

For any of these medicines (tablet or injection) the route is the same: a clinical assessment with a registered prescriber who reviews your BMI, health history, any current medicines, and whether there are reasons a particular treatment is not suitable. There is no shortcut, and any seller offering these medicines without that step is not operating legally.

Wegovy tablets are licensed for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. The injectable options carry similar eligibility thresholds, and if you are researching those specifically, our overview of weight loss injection options and how they are prescribed in the UK covers the criteria in full. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber assesses the full picture, BMI alone does not guarantee any particular outcome.

At nume, every consultation is read personally by a GPhC-registered Independent Prescriber on the day it is submitted. If you are approved, treatment is dispatched the same day for free next-working-day delivery. There are no hidden fees, no subscription and no auto-renewal, each repeat order goes through fresh clinical review. You can verify our pharmacy on the GPhC register (registration 9012878). For a broader look at how treatment costs compare across different formats, our treatment overview page covers what is included in the price. When you are ready to talk to a prescriber about what suits you, check your eligibility and start your free consultation.